700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
|The University of New Mexico, USA|
|ScientificTracks Abstracts: J Psychiatry|
|This study will present data showing that psychopharmacotherapy can help patients with treatment resistant depression recover who have not benefitted from electroconvulsive therapy (ECT). Both pramipexole (PPX) and monoamine oxidase inhibitors (MAOI) often augmented with stimulants will lift a patients’ depression that has been considered treatment resistant quite often. ECT has been considered by experts in the field, the most effective treatment for treatment resistant patients. This study show that this often may not be the case and that certain particular psychopharmacologic treatments should be considered. The data presented includes a clinical sample of 42 consecutive patients treated with high dose PPX who failed at least 4 prior antidepressant treatments and followed for an average of 15.9 months as well as a sample of 20 patients who failed to benefit from ECT who benefitted greatly from high dose PPX. This study additionally reviews already published articles with data showing the therapeutic effects of treatment resistant patients treated with MAOI’s augmented by stimulants. The concept and definition of treatment resistant depression and the presenter’s algorithm for approaching this problem will be reviewed. The dose and management of side effects, as well as the relationship with the patient has a great deal to do with the success of these treatments.|
Jan Fawcett has served as the Chair of the Department of Psychiatry at Rush Medical Center in Chicago while maintaining a private practice for 30 years and then has taught residents for 15 years at the University of New Mexico in Albuquerque, New Mexico as a Professor of Psychiatry, where he supervises a TRD clinic and teaches residents. He has won many awards for his research in depression and suicide prevention and has been the Principal Investigator of 9 NUMH funded grants. He has been the Medical Editor of Psychiatric Annals for 25 years and recently served as Chair of the Mood Disorders Workgroup for DSM-5. He currently continues to practice outpatient psychiatry and runs a Treatment Resistant Depression Clinic at the University of New Mexico and has recently published his first novel, Living Forever.
Email: [email protected]
|PDF | HTML|